The recent disruptions in global chains have highlighted the necessity of securing critical medications like Ivermectin. Relying on overseas manufacturers exposes countries to significant vulnerabilities, including delivery delays, expense fluctuations, and even trade concerns. Moving towards domestic procurement of Ivermectin offers a multitude of